- Home
- HRTX vs SWKH Comparison
HRTX vs SWKH Comparison
Compare HRTX & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- SWKH
- Stock Information
- Founded
- HRTX 1983
- SWKH 1996
- Country
- HRTX United States
- SWKH United States
- Employees
- HRTX N/A
- SWKH N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- SWKH Diversified Financial Services
- Sector
- HRTX Health Care
- SWKH Finance
- Exchange
- HRTX Nasdaq
- SWKH Nasdaq
- Market Cap
- HRTX 180.5M
- SWKH 185.5M
- IPO Year
- HRTX 1987
- SWKH 1999
- Fundamental
- Price
- HRTX $1.07
- SWKH $15.89
- Analyst Decision
- HRTX Strong Buy
- SWKH
- Analyst Count
- HRTX 3
- SWKH 0
- Target Price
- HRTX $5.67
- SWKH N/A
- AVG Volume (30 Days)
- HRTX 2.1M
- SWKH 9.1K
- Earning Date
- HRTX 11-12-2024
- SWKH 11-14-2024
- Dividend Yield
- HRTX N/A
- SWKH N/A
- EPS Growth
- HRTX N/A
- SWKH N/A
- EPS
- HRTX N/A
- SWKH 0.84
- Revenue
- HRTX $137,737,000.00
- SWKH $24,725,000.00
- Revenue This Year
- HRTX $19.15
- SWKH N/A
- Revenue Next Year
- HRTX $21.29
- SWKH $6.17
- P/E Ratio
- HRTX N/A
- SWKH $18.94
- Revenue Growth
- HRTX 12.13
- SWKH N/A
- 52 Week Low
- HRTX $1.04
- SWKH $15.14
- 52 Week High
- HRTX $3.93
- SWKH $18.75
- Technical
- Relative Strength Index (RSI)
- HRTX 23.93
- SWKH 42.92
- Support Level
- HRTX $1.05
- SWKH $15.14
- Resistance Level
- HRTX $1.90
- SWKH $17.10
- Average True Range (ATR)
- HRTX 0.13
- SWKH 0.57
- MACD
- HRTX -0.05
- SWKH -0.10
- Stochastic Oscillator
- HRTX 3.49
- SWKH 35.55
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.